Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Importance of the Underlying Biology
- Industry Size and Major Players
- Analysis of 200 Deals
- Deal Volume
- Largest Deals
- Big Biotech, Mid-Size Pharma, and Big Pharma Deal Volumes
- Deals By Disease Category
- Types of Deals
- Big Biotech Looking for Money and Products
- Nonbiologic Product Deals
- Nucleic Acid Technology Deals
- Business Strategies
- King of Targeted Dealmaking
- Company Acquisitions: Maybe Not
- Divesting: Better Focus and Commercialization
- Passion for Biologics
- Drug Recycling
- Budesonide Story
- Drug Combination
- Industry-Shaping Events, 2008-2009
- Impact of Big Pharma Consolidation
- Safety Concerns
- Biotech Is Hurting
- Industry Drivers
- Ten Drivers of the Autoimmune and Infl ammatory Disease Therapy Area
- Factors Holding Back the Autoimmune and Infl ammatory Disease Industry
- Industry Outlook
Tables
- 1. Decision Resources Analysts' Input on the Current Status and Future
Directions of Autoimmune and Infl ammatory Disease Therapies
- 2. Autoimmune and Infl ammatory Diseases: Nonbiologic Product Deals,
2007-2009
- 3. Autoimmune and Infl ammatory Diseases: Nucleic Acid Therapeutics Deals,
2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Antibody Deals, 2007-2009
- 5. Autoimmune and Infl ammatory Diseases: Peptide and Recombinant Protein
Deals, 2007-2009
- 6. Autoimmune and Infl ammatory Diseases: Drug Delivery and Formulation
Technology Deals, 2007-2009 .
Figures
- 1. Autoimmune and Infl ammatory Diseases: Top 25 Companies by Worldwide
Sales, 2008 and 2014
- 2. Autoimmune and Infl ammatory Diseases: Deal Volume Based on Potential
Deal Size, 2007-2009
- 3. Autoimmune and Infl ammatory Diseases: the Largest Deals, 2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Big Pharma, Mid-Size Pharma, and
Big Biotech Deal Volume, 2007-2009
- 5. Deals in the Autoimmune and Infl ammatory Therapy Area by Categories of
Disease, 2007-2009
- 6. Types of Autoimmune and Infl ammatory Disease Deals, 2007-2009
- 7. NF-KB Pathway
- 8. Development Timeline for the Tumor Necrosis Factor-Alpha Blocker Humira
(adalimumab)
Mentioned in This Report
- Abbott
- Ablynx
- Actimis Pharmaceuticals
- Acusphere
- Adeona Pharmaceuticals
- affibody
- Airmid
- Alantos Pharmaceuticals
- Alba Therapeutics
- Albireo
- Alizyme Therapeutics
- Alkermes
- Alloksys Life Sciences
- Almirall
- Alnylam Pharmaceuticals
- Altana
- Amgen
- Amira Pharmaceuticals
- Anesiva
- AnGes MG
- Anthera Pharmaceuticals
- Antitope
- Aphios
- Arachnova Therapeutics
- Archemix
- Argenta Discovery
- Array BioPharma
- Arrow International
- Aspen Pharmacare
- Astellas Pharma
- AstraZeneca
- Atlantic Healthcare
- Biogen Idec
- Biolex
- BioLineRx
- Biolipox
- BioMarin Pharmaceuticals
- Bionomics
- Biotica
- Biovitrum
- Boehringer Ingelheim
- Brigham and Women' s Hospital
- Bristol-Myers Squibb
- Burrill & Co.
- CalciMedica
- Calistoga Pharmaceuticals
- Cambridge Antibody
- Technology
- Cambridge Biotechnology
- Can-Fite Biopharma
- Catalyst Biosciences
- CBR Institute for Biomedical
- Research
- Celgene
- Cell Signaling Technology
- Cellatope
- Celldex Therapeutics
- Cellzome
- Centocor
- Cephalon
- Cequent Pharmaceuticals
- CEVEC Pharmaceuticals
- Chiesi Farmaceutici
- Chugai
- Chroma Therapeutics
- Clinquest
- Codon Devices
- Compugen
- Cosmo
- Cypress Bioscience
- Daiichi-Sankyo
- Debiopharm
- Dongguan Kaifa Biomedicine
- Dr Falk Pharma
- Dr Reddy' s Laboratories
- Dr. Falk Pharma
- Dyax
|
Related Report
|
View Cart
